Infliximab in ulcerative colitis

被引：17

作者：

Aberra, Faten N. ^{[1
]}

Lichtenstein, Gary R. ^{[1
]}

机构：

[1] Hosp Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2006年 / 35卷 / 04期

关键词：

D O I：

10.1016/j.gtc.2006.09.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Until recently development of new medical therapies for the treatment of patients who have ulcerative colitis (UC) has been somewhat stagnant. In 2005, results of two prospective, randomized, placebo-controlled clinical trials demonstrated that infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha) tested initially in patients who had Crohn's disease and now a standard agent in the treatment of these patients, is efficacious for treatment of UC. This article provides information about the evolution of anti-TNF therapy for the treatment of UC.

引用

页码：821 / +

页数：17

共 74 条

[1]

[Anonymous], REMICADE INFLIXIMAB

[2]

Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis [J].

Armstrong, AM ;

Foulkes, R ;

Jennings, G ;

Gannon, C ;

Kirk, SJ ;

Gardiner, KR .

BRITISH JOURNAL OF SURGERY, 2001, 88 (02) :235-240

[3]

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[4]

Bazzoni F, 1995, J INFLAMM, V45, P221

[5]

The tumor necrosis factor ligand and receptor families [J].

Bazzoni, F ;

Beutler, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1717-1725

[6]

Therapeutic monoclonal antibodies [J].

Breedveld, FC .

LANCET, 2000, 355 (9205) :735-740

[7]

TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].

BREESE, EJ ;

MICHIE, CA ;

NICHOLLS, SW ;

MURCH, SH ;

WILLIAMS, CB ;

DOMIZIO, P ;

WALKERSMITH, JA ;

MACDONALD, TT .

GASTROENTEROLOGY, 1994, 106 (06) :1455-1466

[8]

DETECTION OF MESSENGER-RNAS FOR MACROPHAGE PRODUCTS IN INFLAMMATORY BOWEL-DISEASE BY INSITU HYBRIDIZATION [J].

CAPPELLO, M ;

KESHAV, S ;

PRINCE, C ;

JEWELL, DP ;

GORDON, S .

GUT, 1992, 33 (09) :1214-1219

[9]

The incidence and management of infusion reactions to infliximab: A large center experience [J].

Cheifetz, A ;

Smedley, M ;

Martin, S ;

Reiter, M ;

Leone, G ;

Mayer, L ;

Plevy, S .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (06) :1315-1324

[10]

The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].

Colombel, JF ;

Loftus, EV ;

Tremaine, WJ ;

Egan, LJ ;

Harmsen, WS ;

Schleck, CD ;

Zinsmeister, AR ;

Sandborn, WJ .

GASTROENTEROLOGY, 2004, 126 (01) :19-31

← 1 2 3 4 5 6 7 8 →